Study Background

Vaginal atrophy (Vulvovaginal Atrophy), which commonly occurs in postmenopausal women, significantly impairs quality of life. Current therapies are estrogen‑based topical agents, but long‑term use carries safety concerns. Azure Biotech has developed AZU-101 as a non‑steroidal alternative. This Phase 2 study is intended to validate this differentiated approach.

Study Design

In this Phase 2 trial, daily intravaginal administration will be used to assess safety, tolerability, and systemic pharmacokinetics (PK). The primary endpoint is safety and tolerability; the secondary endpoint is improvement of vaginal epithelium. Eligible participants are postmenopausal women, and enrollment is ongoing. The study is slated to commence in June 2026, with the completion date not yet defined.

Expected Benefits

If AZU-101 delivers a hormone‑independent mechanism distinct from existing estrogen therapies, it could minimize adverse events and enable long‑term use. This positions the product to become a new standard in the vaginal atrophy market. Success would allow Azure Biotech to expand its pipeline and strengthen its attractiveness for investment.

Risk Factors

Because the program is in Phase 2, efficacy data are limited, and any safety concerns could delay development timelines. Moreover, the vaginal atrophy market is already highly competitive; without differentiated clinical outcomes, commercialization may be challenging. Investors should therefore monitor trial progress closely.